Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 3
1975 1
1977 1
1987 1
1989 1
1991 5
1992 3
1993 3
1994 5
1995 4
1996 8
1997 4
1998 1
1999 2
2000 3
2002 1
2004 1
2005 1
2006 2
2007 1
2010 1
2011 1
2012 3
2013 2
2014 5
2015 2
2017 2
2018 4
2019 7
2020 2
2021 4
2022 2
2023 4
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Results by year

Filters applied: . Clear all
Page 1
SYNGAP1 heterozygosity disrupts sensory processing by reducing touch-related activity within somatosensory cortex circuits.
Michaelson SD, Ozkan ED, Aceti M, Maity S, Llamosas N, Weldon M, Mizrachi E, Vaissiere T, Gaffield MA, Christie JM, Holder JL Jr, Miller CA, Rumbaugh G. Michaelson SD, et al. Among authors: weldon m. Nat Neurosci. 2018 Dec;21(12):1-13. doi: 10.1038/s41593-018-0268-0. Epub 2018 Nov 21. Nat Neurosci. 2018. PMID: 30455457 Free PMC article.
Retelling urban legends.
Fox Tree JE, Weldon MS. Fox Tree JE, et al. Among authors: weldon ms. Am J Psychol. 2007 Fall;120(3):459-76. Am J Psychol. 2007. PMID: 17892088
99mTc-HMPAO planar white cell scanning.
Weldon MJ. Weldon MJ. Scand J Gastroenterol Suppl. 1994;203:36-42. doi: 10.3109/00365529409091395. Scand J Gastroenterol Suppl. 1994. PMID: 7973447 Review.
Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial.
Jagannathan P, Chew KW, Giganti MJ, Hughes MD, Moser C, Main MJ, Monk PD, Javan AC, Li JZ, Fletcher CV, McCarthy C, Wohl DA, Daar ES, Eron JJ, Currier JS, Singh U, Smith DM, Fischer W; ACTIV-2/A5401 Study Team. Jagannathan P, et al. EClinicalMedicine. 2023 Oct 6;65:102250. doi: 10.1016/j.eclinm.2023.102250. eCollection 2023 Nov. EClinicalMedicine. 2023. PMID: 37855026 Free PMC article.
86 results